Short version: rapamycin is the most reliable life-extending drug we have. In mice. In people, no trial has shown it slows aging, and the two best human trials so far found no benefit on their main outcome, with more side effects.
What's claimed
Rapamycin (and its cousin everolimus) gets sold as the anti-aging pill you can actually take. It's in longevity clinics, on podcasts, in off-label prescriptions. So: does it slow aging in humans?
The mouse case is genuinely strong
This is the part that isn't hype.
- Harrison et al 2009, Nature. Rapamycin fed to mice starting at 600 days, which is old age for a mouse. It extended both median and maximum lifespan: a 14% increase for females and 9% for males at the age of 90% mortality. First drug ever shown to do this in a mammal. (PMID 19587680)
- Miller et al 2011, J Gerontol A. Rapamycin from 9 months extended median survival by 10% in males and 18% in females. The same study ran resveratrol and simvastatin in parallel, and neither moved survival. (PMID 20974732)
The replication matters: three independent test sites, both sexes, and it still worked when started late. That's why the geroscience literature calls rapamycin "the most reproducible pharmacological geroprotector" in the field. (GeroScience 2026, PMID 42126807)
The human case is thin, and the two real trials lean negative
- PEARL trial, Aging 2025. 48 weeks, double-blind, healthy adults, weekly low-dose rapamycin (5 or 10 mg) vs placebo. The primary outcome was visceral fat. It did not change (p = 0.942). Some secondary signals did show up, mostly in women on the higher dose: lean tissue mass and self-reported pain improved. Adverse events were similar across groups, and blood markers stayed normal. So: 1-year safety looked okay, but the thing it was designed to test did not move. (PMID 40188830)
- RAPA-EX-01, 2026. 40 sedentary adults aged 65-85, weekly rapamycin 6 mg vs placebo, both doing a home exercise program for 13 weeks. The primary outcome (30-second chair-stand reps) did not improve: -2.13 reps vs placebo, p = 0.089. The pre-specified sensitivity analyses actually favoured placebo and reached significance. Side effects were higher on rapamycin (99 vs 63 events), including one possibly drug-related serious infection (pneumonia). (PMID 41985884)
Here's the part people skip: no human trial has measured lifespan or mortality. That endpoint doesn't exist for rapamycin. Every human study measures a surrogate, visceral fat, chair-stands, immune markers, and surrogates can move in either direction without telling you anything about how long you live.
And rapamycin is an immunosuppressant. The mechanism that might slow aging is the same one that raises infection risk. That's not a side note. It's the whole trade.
The gap
Mouse lifespan data is the best available evidence for any longevity drug, and rapamycin's is the best of that bunch. But a mouse result is not a human result. Plenty of drugs extend mouse lifespan and fail in people. Rapamycin's human evidence so far is short, small, and either flat or slightly negative.
Sources
- Harrison DE et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009. PMID 19587680
- Miller RA et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A, 2011. PMID 20974732
- PEARL trial results. Influence of rapamycin on safety and healthspan metrics after one year. Aging, 2025. PMID 40188830
- RAPA-EX-01. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults. J Cachexia Sarcopenia Muscle, 2026. PMID 41985884
- Bench to bedside: is rapamycin headed for the docTOR? GeroScience, 2026. PMID 42126807
Part of a series: one claim at a time, traced to the paper it came from. Reply below, no account needed, or email 7ens@ilands.app.